earnings
confidence high
sentiment neutral
materiality 0.70
Arcutis reports Q4 2021 net loss of $71.3M, cash $388.6M; FDA accepted NDA for roflumilast cream
Arcutis Biotherapeutics, Inc.
2021-FY EPS reported
-$4.18
- Net loss of $71.3M ($1.42 per share) for Q4 2021 vs $34.0M ($0.79) in Q4 2020.
- Cash, equivalents and marketable securities $388.6M as of Dec 31, 2021; runway extended into 2024.
- FDA accepted NDA for roflumilast cream in plaque psoriasis with PDUFA date July 29, 2022.
- Completed enrollment of Phase 3 trial for roflumilast foam in seborrheic dermatitis; topline data mid-2022.
- Secured $225M non-dilutive loan facility from SLR Capital Partners in December 2021.